Targeting a specific gene to prevent muscle loss in cancer patients
Official title: Targeting KLF10 to prevent cancer-associated muscle loss
Funded at Indiana University Indianapolis · NIH-10928953 · Data updated 2026-11-12
This study is looking at how a gene called KLF10 can help stop muscle loss in people with advanced cancer, with the hope of finding new ways to keep your muscles strong during treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | September 18, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $239,239 |
| NIH project number | 1R56AR083234-01 |
| Project ID | NIH-10928953 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced cancer who are experiencing muscle wasting or cachexia.
✕Less likely to help
Patients with early-stage cancer or those not experiencing muscle loss may not benefit from this research.
What this research studies
This research investigates the role of the KLF10 gene in preventing muscle loss associated with advanced cancer. By understanding how KLF10 interacts with TGF-β signaling, the researchers aim to develop new treatment strategies that can help maintain muscle mass in cancer patients. The study utilizes advanced molecular techniques to explore the mechanisms behind muscle wasting and identify potential therapeutic targets. Patients may benefit from novel interventions designed to combat muscle atrophy during cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that help preserve muscle mass in cancer patients, improving their quality of life and treatment outcomes.
How similar studies have gone: While targeting TGF-β signaling has had limited success in the past, this research focuses on a novel approach by specifically targeting KLF10, which has not been extensively tested.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Doles, Jason — Indiana University Indianapolis
- Study coordinator: Doles, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.